Context Therapeutics CNTX

NASDAQ CNTX
$0.17 +0.00 (+0.00%)
At close: Nov 19, 2026 · 4:00 PM EST

Context Therapeutics (CNTX) stock price is $0.17, unchanged on the day, as of Nov 19, 2026. It has a market cap of $15.24Mn, and is classified in the Biotechnology industry (Healthcare sector).

Key Stats
Market Cap15.24 Mn
P/E-0.35
FCF (Yr)-26.42 Mn
ROA (Yr)-43.60
EV to EBIT3.96
Net Income (Yr)-36.12 Mn
Enterprise Value-182.70 Mn
Add ratio to table…

About

Context Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for solid tumors. The company's pipeline consists of three product candidates that each combine a tumor associated antigen binding domain with a CD3 T cell engaging domain. CTIM 76 targets Claudin 6 a tight junction protein overexpressed in ovarian endometrial testicular and other solid tumors. CT 95 targets Mesothelin a membrane protein found in…

Read more ↓
Sector: Healthcare Sector rationale Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors, which falls directly under the Biotechnology and Pharmaceuticals industries within Healthcare. Its revenue model is based on licensing and collaboration agreements for these medical candidates, and its ultimate customers will be healthcare providers and patients. Industry: Biotechnology Biotechnology Primary Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies, which are recombinant proteins. Its revenue is derived from collaboration and licensing agreements, such as the $11 million upfront payment from BioAtla for the CT 202 asset. Classified using BQ-MICS CIK: 0001842952
Peer percentiles

How Context Therapeutics ranks

Ranked against the 690 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 20, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/ENegative earnings −0.37xMedian 16.4x 15th
  • P/FCFNegative free cash flow −0.46xMedian 15.0x 13th
  • P/Operating cash flowNegative operating cash flow −0.46xMedian 14.9x 13th
  • P/S 8.00xMedian 8.18x 51st
  • P/B 0.50xMedian 2.03x 84th
  • P/Tangible book 0.50xMedian 2.23x 85th
  • EV/EBITDANet cash exceeds market value 0.41xMedian 14.9x Not meaningful —
  • EV/EBITNet cash exceeds market value 0.41xMedian 17.0x Not meaningful —
  • EV/RevenueNet cash exceeds market value −9.62xMedian 6.79x Not meaningful —
  • EV/FCFNet cash exceeds market value 0.55xMedian 19.7x Not meaningful —
  • EV/Operating cash flowNet cash exceeds market value 0.55xMedian 15.4x Not meaningful —
  • PEG (3Y EPS CAGR)Negative earnings −0.01Median 0.40 Not meaningful —
Peer group

Peer Comparison

Companies in the Biotechnology
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 PETV PetVivo Holdings, Inc. 3,096.39 Bn-336,007.552.84 Mn0.00 Bn
2 LLY ELI LILLY & Co 1,202.70 Bn43.610.00 Mn49.50 Bn
3 JNJ Johnson & Johnson 649.77 Bn40.370.00 Mn44.65 Bn
4 ABBV AbbVie Inc. 507.00 Bn49.020.00 Mn80.90 Bn
5 MRK Merck & Co., Inc. 329.70 Bn134.410.00 Mn53.78 Bn
6 NVS Novartis Ag 291.91 Bn17.910.00 Mn-
7 AMGN Amgen Inc 236.26 Bn25.160.00 Mn54.01 Bn
8 CNTX Context Therapeutics Inc. 0.02 Bn-0.350.00 Mn-